Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
In modern society, endometrial cancer (EC) and atypical hyperplasia is the most frequent
desease which can affect the fertility of young patients. For young patients, there is a
growing need to treat tumors and fertility sparing. Advaced studies have confirmed
thatfertility preservation therapy has better tumor and pregnancy outcomes in specific
patients with early gynecological tumors. Clinically, evidence-based guidelines are urgently
needed to guide the screening and treatment of women who are suitable for fertility
preservation. Fertility-sparing treatment predominantly involves the use of oral progestins
and levonorgestrel-releasing intrauterine devices, which have been shown to be feasible and
safe in women with early stage EC and minimal or no myometrial invasion. However, data on the
efficacy and safety of conservative management strategies are primarily based on
retrospective studies.The present study aims to compared the therapeutic effect of
Medroxyprogesterone acetate (MPA) and Levonorgestrel-releasing intrauterine system (LNG-IUS)
in early-stage endometrioid carcinoma and atypical hyperplasia patients